Need to remember that the primary objective of this trial is safety, not efficacy. Consider holding the reins with respect to comments regarding efficacy, although as conservatively stated in the press release "early indications suggest promising efficacy in both systemic and cutaneous T cell lymphomas...".
Have personally bought back in a small position today after the 'debacle' of a situation with the company options previously (and continuing sliding share price). Perhaps management can turn this ship around after those mishaps. New share price lows below October lows would indicate significant underlying issues with company management though - let's see how things go. I'm optimistic considering what appears to be promising results, which should (hopefully) translate to improved patient treatment (our ultimate aim overall) - now let's see if management and the share market work kindly in tandem to encourage company growth.
